Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Discontinuing Statins in Older Adults without Cardiovascular Disease.

Created on 09 Nov 2026

Authors

Nicolas Rodondi, Moa Lina Haller, Julia Bianca Bardoczi, Luise Adam, Manuel Raphael Blum, Baris Gencer, Tamar Itach, Julian Simon Flury, Lara Aurora Brockhus, Philipp Stefan Aebi, Martin Feller, Claudia Gregoriano, Roxane de la Harpe, Jacobijn Gussekloo, Nathalie Schwab, Pierre Poulizac, Simon Pieter Mooijaart, Jürg-Hans Beer, Stéphanie Baggio, Sebastian Carballo, Fabrice Bonnet, Dina Zekry, Luca Gabutti, Maria Monika Wertli, Drahomir Aujesky, Douglas Charles Bauer, Rita Fran Redberg, Philip Greenland, Rosalinde Klazina Elisabeth Poortvliet, Philipp Schuetz, Marie Méan, Alan Gary Haynes, Sven Trelle, STREAM Investigators

Published in

The New England journal of medicine. Nov 07, 2026. Epub Nov 07, 2026.

Abstract

Whether discontinuing statin therapy in older adults with at least two chronic conditions but no known cardiovascular disease affects the time to a first cardiovascular event is not well characterized.
We conducted an international, open-label, randomized, controlled trial that enrolled adults at least 70 years of age who were taking statins for primary prevention. Participants were randomly assigned in a 1:1 ratio to either discontinue or continue statin therapy and other lipid-lowering therapies. The primary outcome was a composite of nonfatal myocardial infarction, nonfatal ischemic stroke, or death from any cause, whichever occurred first. The primary analysis assessed noninferiority on the basis of the between-group difference in restricted mean event-free survival time at 2 years, with a noninferiority margin of -5.2 weeks.
A total of 1880 participants underwent randomization: 938 were assigned to the discontinuation group and 942 to the continuation group. The mean age of the participants was 77.5 years, and 46.9% were women. The between-group difference in the restricted mean event-free survival time at 2 years was -2.0 weeks (95% confidence interval, -3.7 to -0.3; P<0.001 for noninferiority). Over a median follow-up of 103 weeks, 119 participants (12.7%) in the discontinuation group and 87 (9.2%) in the continuation group had a primary-outcome event. At least one serious adverse event occurred in 43.0% of the participants in the discontinuation group and in 39.8% in the continuation group.
Among older adults with at least two chronic conditions but no known cardiovascular disease, discontinuation of statin therapy was noninferior to continuation with respect to major cardiovascular events or death from any cause at 2 years. (Funded by the Swiss National Science Foundation; STREAM ClinicalTrials.gov number, NCT05178420.).

PMID:
43001742
Bibliographic data and abstract were imported from PubMed on 09 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement